Physician profile
Roberto Canales
NPI 1093827255
$2,859.21
in general payments reported to CMS, 2019-2025
28 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $147 · 2021: $265 · 2022: $702 · 2023: $620 · 2024: $335 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $338.31 | 2020-2025 | Adynovate, Advate, Elaprase |
| Allergan, INC. | $255.84 | 2019-2020 | |
| Genentech USA, INC. | $231.32 | 2023-2025 | Hemlibra |
| Genzyme Corporation | $191.18 | 2022-2025 | |
| Novo Nordisk INC | $179.72 | 2019-2025 | Alhemo, Esperoct, Rebinyn |
| Alexion Pharmaceuticals, INC. | $168.99 | 2019-2023 | Ultomiris |
| Merck Sharp & Dohme LLC | $164.83 | 2019-2025 | Keytruda |
| Adaptive Biotechnologies Corporation | $154.24 | 2022-2023 | Clonoseq |
| Grifols USA, LLC | $118.72 | 2019-2022 | |
| Csl Behring | $115.26 | 2022-2025 | Hemgenix, Idelvion, Afstyla |
| Abbvie INC. | $114.69 | 2021 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $78.78 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $74.67 | 2019-2021 | |
| Daiichi Sankyo INC. | $74.01 | 2022-2023 | Enhertu |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $69.94 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $63.55 | 2021-2023 | |
| Shire North American Group INC | $62.67 | 2019 | |
| Octapharma USA, INC. | $60.14 | 2020-2022 | |
| Amgen INC. | $52.01 | 2022-2023 | Nplate |
| Springworks Therapeutics, INC. | $40.62 | 2025 | Gomekli |
| Medtronic, INC. | $35.15 | 2023 | Stealthstation S8 Platform |
| Pfizer INC. | $26.38 | 2025 | |
| Servier Pharmaceuticals LLC | $20.52 | 2023 | |
| Coherus Oncology, INC. | $19.39 | 2023 | |
| Horizon Therapeutics Plc | $17.49 | 2022 | |
| Uswm, LLC | $17.29 | 2025 | Iwilfin |
| Morphosys, US INC. | $14.50 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Canales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.